Cover Image
市場調查報告書

化療引起噁心嘔吐(CINV)之上市藥及研發中藥物市場(Aloxi、Zofran Generic、Kytril Generic、Emend、Akynzeo、SUSTOL、Rolapitant):全球產業、市場規模、市佔率、成長率、動態分析、預測

CINV Existing and Pipeline Drugs Market (Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL and Rolapitant) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

出版商 Transparency Market Research 商品編碼 322861
出版日期 內容資訊 英文 74 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
化療引起噁心嘔吐(CINV)之上市藥及研發中藥物市場(Aloxi、Zofran Generic、Kytril Generic、Emend、Akynzeo、SUSTOL、Rolapitant):全球產業、市場規模、市佔率、成長率、動態分析、預測 CINV Existing and Pipeline Drugs Market (Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL and Rolapitant) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
出版日期: 2014年12月29日 內容資訊: 英文 74 Pages
簡介

從各種資訊來源可得知,接受化療的癌症患者中,有7∼8成的主訴症狀為噁心與嘔吐。化療所引起的噁心及嘔吐(CINV)會使人極度衰弱。儘管目前有許多藥物試圖控制CINV,但仍未出現能有效解決此症狀的藥物。

本報告針對化療引起噁心嘔吐(CINV)的上市藥物及研發中藥物進行調查,彙整了CINV的概要、治療方法、未滿足需求、主要上市藥物的概要、市場收益的變動與預測、研發中藥五的狀況與SWOT分析、各地區動態、競爭環境與主要企業檔案等豐富內容,為各位客戶提供如後。

第1章 前言

第2章 實施概要

第3章 全球CINV上市藥物及研發中藥物的市場概要

  • 化療引起的噁心與嘔吐(Chemotherapy induced nausea and vomiting, CINV)
    • CINV的病源/起因
    • CINV的病理機制
    • CINV的治療提案
    • CINV市場中的未滿足需求
  • 市場動態
    • 促進因素
      • 接受化療的患者人數增加
      • 預期在2014年到2020年間可獲得核可的新CINV藥物
    • 抑制因素
      • 在預測期間主要CINV藥物的專利到期
      • 發現新藥與研發過程相關的嚴格法律程序以及高成本
    • 市場機會
      • 著重於開發預防CINV之突破性治療方法,例如固定劑量組方產品以及其他加強治療效果的新產品
      • 聚焦於在CINV藥物方面蘊藏大量潛力的開發中國家
  • 活動影響分析

第4章 全球CINV上市藥物及研發中藥物市場:各主要藥劑利潤的變動與預測

  • 概要
  • 已上市之CINV藥物市場
    • 各主要藥劑利潤的變動與預測
    • 各主要藥劑患者人數的變動與預測
    • 比較分析:各主要藥劑的收益實績與預測
    • Aloxi (palonosetron)
      • 市場收益的變動與預測
    • Zofran Generic (ondansetron)
      • 市場收益的變動與預測
    • Kytril Generic (granisetron)
      • 市場收益的變動與預測
    • Emend (aprepitant)
      • 市場收益的變動與預測
    • Akynzeo (netupitant-palonosetron FDC)
      • 市場收益的變動與預測
  • CINV研發中藥物市場
    • SUSTOL (granisetron injection extended release)
      • 市場收益的變動與預測
      • SWOT分析
      • SUSTOL的第三期試驗研究
        • 主要效力結果:接受MEC的患者完全反應
        • 主要效力結果:接受HEC的患者完全反應
    • Rolapitant
      • 市場收益的變動與預測
      • SWOT分析
      • Rolapitant的效力分析概要

第5章 全球CINV上市藥物及研發中藥物市場:各地區收益變動與預測

  • 概要
    • 市場收益的變動與預測:各地區
    • 估計患者人數:各地區
  • 北美
    • 市場收益的變動與預測
    • 估計患者人數:各研發中藥物
  • 歐洲
    • 市場收益的變動與預測
    • 估計患者人數:各研發中藥物
  • 亞太地區
    • 市場收益的變動與預測
  • 其他地區
    • 市場收益的變動與預測

第6章 競爭情勢

  • 競爭情勢

第7章 企業檔案

  • GlaxoSmithKline plc
  • Helsinn Holding S.A.
  • Heron Therapeutics Inc.
  • Merck & Co.、 Inc
  • Tesaro Inc.
    • 企業概要
    • 財務概要
    • 產品檔案
    • 商業策略
    • 最新發展動態等等

圖表

目錄

Chemotherapy induced nausea and vomiting (CINV) refers to the nausea and vomiting associated with cancer chemotherapy. Various sources indicate that approximately 70% to 80% cancer patients undergoing chemotherapy exhibit nausea and vomiting as major symptoms. Chemotherapy induced nausea and vomiting is an extremely debilitating condition. Although there are currently a number of drugs available to manage CINV, they do not effectively address the symptoms of this condition. The report on CINV existing and pipeline drugs market offers an insightful and in-depth assessment of the current as well as future market potential of CINV drugs. Aloxi (palonosetron), Zofran generic (ondansetron), Kytril generic (granisetron), Emend (aprepitant) and Akynzeo (netupitant-palonosetron FDC) are the major currently available drugs extensively studied in the report. The historical market size and forecast for each of these drugs (except for Akynzeo, as the U.S. Food and Drug Administration (FDA) approved it only in October 2014) in terms of revenue (USD Million) has been provided in the report for the period from 2012 to 2020. In addition, the compounded annual growth rate (CAGR) for each of these drugs has been provided in the report for the forecast period from 2014 to 2020, considering 2012 and 2013 as base years. The report also studies the CINV patient pool for each of these drugs. The market size and CAGR for Akynzeo have been determined for the years from 2015 to 2020.

The report also provides extensive analysis of the pipeline drugs SUSTOL (extended release granisetron injection) and rolapitant, including the status of current clinical trials and future sales projection in terms of USD million. The future sales projection of both these pipeline drugs has also been provided for the North American and European regions. The study also provides estimated patient pool for both these pipeline drugs, broken down by North America and Europe.

In this research study, the global market for CINV drugs has been geographically segmented into four regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The CINV drugs market size and forecast in terms of revenue for each region has been provided for the period from 2012 to 2020 along with the CAGR for the forecast period from 2014 to 2020. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities. The market overview chapter provides information such as major subtypes of CINV, the etiology of CINV, the pathogenesis of CINV, major emetogenic chemotherapeutic agents, treatment recommendations for CINV and unmet needs in the CINV market. A section on event impact analysis has also been provided in the market overview chapter of the report on CINV existing and pipeline drugs market.

The report on chemotherapy induced nausea and vomiting drugs market also includes a section on the competitive landscape of the market, wherein the qualitative analysis of leading players in the global CINV drugs market is presented. The report concludes with the profiles of major players in the chemotherapy induced nausea and vomiting drugs market such as GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc. and Tesaro, Inc. Each company profile comprises information such as company overview, financial overview (selling, general and administrative expenses, research and development expenses and annual revenue for consecutive three years 2011, 2012 and 2013), current and pipeline product portfolio, business strategies and recent developments.

The global CINV existing and pipeline drugs market is segmented as follows:

CINV Existing and Pipeline Drugs Market Revenue (USD Million), by Major Drugs

  • Aloxi (palonosetron)
  • Zofran Generic (ondansetron)
  • Kytril Generic (granisetron)
  • Emend (aprepitant)
  • Akynzeo (netupitant-palonosetron)
  • SUSTOL (extended release granisetron injection)
  • Rolapitant

CINV Existing and Pipeline Drugs Market Revenue (USD Million), by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Table of Contents

Chapter 1 Preface

  • 1.1 Report Description
  • 1.2 Market Segmentation
  • 1.3 Research Methodology
    • 1.3.1 Assumptions
    • 1.3.2 Sources
      • 1.3.2.1 Secondary Research
      • 1.3.2.2 Primary Research
    • 1.3.3 Models
  • 1.4 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot: Global CINV Existing and Pipeline Drugs Market (2013 & 2020)
  • 2.2 Global CINV Drugs Market, by Major Drugs, 2013 (USD Million)
  • 2.3 Comparative Analysis: Global CINV Drugs Market Revenue, by Geography, 2013 & 2020 (Value %)

Chapter 3 Global CINV Existing and Pipeline Drugs Market Overview

  • 3.1 Chemotherapy Induced Nausea and Vomiting (CINV)
    • 3.1.1 Aetiology/Causes for CINV
    • 3.1.2 Pathogenesis of CINV
    • 3.1.3 Treatment Recommendations for CINV
    • 3.1.4 Unmet Needs in the CINV Market
  • 3.2 Market Dynamics
    • 3.2.1 Drivers
      • 3.2.1.1 Growing number of patients undergoing chemotherapy
      • 3.2.1.2 Anticipated approval of new CINV drugs during the forecast period from 2014 to 2020
    • 3.2.2 Restraints
      • 3.2.2.1 Patent expirations of major CINV drugs during the projected period
      • 3.2.2.2 Strict regulatory pathway and high cost associated with the new drug discovery and development
    • 3.2.3 Opportunities
      • 3.2.3.1 Emphasis on developing breakthrough therapy for the prevention of CINV such as fixed-dose combination product and other innovative products with enhanced therapeutic efficacy
      • 3.2.3.2 Focusing on developing nations as they present immense market potential for CINV drugs
  • 3.3 Event Impact Analysis

Chapter 4 Global CINV Existing and Pipeline Drugs Market Revenue, by Major Drugs, 2012 - 2020 (USD Million)

  • 4.1 Overview
  • 4.2 CINV Existing Drugs Market
    • 4.2.1 Global CINV Drugs Market Revenue, by Major Drugs, 2012 - 2020 (USD Million)
    • 4.2.2 Global CINV Estimated Patient Pool, by Major Drugs, 2012 - 2020 (Thousands)
    • 4.2.3 Comparative Analysis: Global CINV Drugs Market Revenue, by Major Drugs, 2013 & 2020 (Value %)
    • 4.2.4 Aloxi (palonosetron)
      • 4.2.4.1 Global Aloxi Market Revenue, 2012 - 2020 (USD Million)
    • 4.2.5 Zofran Generic (ondansetron)
      • 4.2.5.1 Global Zofran Generic Market Revenue, 2012 - 2020 (USD Million)
    • 4.2.6 Kytril Generic (granisetron)
      • 4.2.6.1 Global Kytril Generic Market Revenue, 2012 - 2020 (USD Million)
    • 4.2.7 Emend (aprepitant)
      • 4.2.7.1 Global Emend Market Revenue, 2012 - 2020 (USD Million)
    • 4.2.8 Akynzeo (netupitant-palonosetron FDC)
      • 4.2.8.1 Global Akynzeo Market Revenue, 2015 - 2020 (USD Million)
  • 4.3 CINV Pipeline Drugs Market
    • 4.3.1 SUSTOL (granisetron injection extended release)
      • 4.3.1.1 Global SUSTOL Market Revenue, 2016 - 2020 (USD Million)
      • 4.3.1.2 SWOT Analysis for SUSTOL
      • 4.3.1.3 Overview of SUSTOL Phase III study
        • 4.3.1.3.1 Primary Efficacy Results: Complete Response with Patients Receiving MEC
        • 4.3.1.3.2 Primary Efficacy Results: Complete Response with Patients Receiving HEC
    • 4.3.2 Rolapitant
      • 4.3.2.1 Global Rolapitant Market Revenue, 2015 - 2020 (USD Million)
      • 4.3.2.2 SWOT Analysis for Rolapitant
      • 4.3.2.3 Overview of Rolapitant Efficacy Analysis

Chapter 5 Global CINV Existing and Pipeline Drugs Market Revenue, by Geography, 2012 - 2020 (USD Million)

  • 5.1 Overview
    • 5.1.1 Global CINV Drugs Market Revenue, by Geography, 2012 - 2020 (USD Million)
    • 5.1.2 Global CINV Estimated Patient Pool, by Geography, 2012 - 2020 (Thousands)
  • 5.2 North America
    • 5.2.1 North America CINV Drugs Market Revenue, 2012 - 2020 (USD Million)
    • 5.2.2 North America CINV Pipeline Drugs Market Revenue, 2015 - 2020 (USD Million)
    • 5.2.3 North America CINV Estimated Patient Pool, by Pipeline Drug, 2015 - 2020 (Thousands)
  • 5.3 Europe
    • 5.3.1 Europe CINV Drugs Market Revenue, 2012 - 2020 (USD Million)
    • 5.3.2 Europe CINV Pipeline Drugs Market Revenue, 2016 - 2020 (USD Million)
    • 5.3.3 Europe CINV Estimated Patient Pool, by Pipeline Drug, 2016 - 2020 (Thousands)
  • 5.4 Asia-Pacific
    • 5.4.1 Asia-Pacific CINV Drugs Market Revenue, 2012 - 2020 (USD Million)
  • 5.5 Rest of the World (RoW)
    • 5.5.1 RoW CINV Drugs Market Revenue, 2012 - 2020 (USD Million)

Chapter 6 Competitive Landscape

  • 6.1 Competitive Landscape

Chapter 7 Company Profiles

  • 7.1 GlaxoSmithKline plc
    • 7.1.1 Company Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Product Portfolio
    • 7.1.4 Business Strategies
    • 7.1.5 Recent Developments
  • 7.2 Helsinn Holding S.A.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Product Portfolio
    • 7.2.4 Business Strategies
    • 7.2.5 Recent Developments
  • 7.3 Heron Therapeutics, Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Product Portfolio
    • 7.3.4 Business Strategies
    • 7.3.5 Recent Developments
  • 7.4 Merck & Co., Inc.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Product Portfolio
    • 7.4.4 Business Strategies
    • 7.4.5 Recent Developments
  • 7.5 Tesaro, Inc.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Product Portfolio
    • 7.5.4 Business Strategies
    • 7.5.5 Recent Developments

List of Figures

  • FIG. 1 CINV Existing and Pipeline Drugs: Market Segmentation
  • FIG. 2 Global CINV Drugs Market, by Major Drugs, 2013 (USD Million)
  • FIG. 3 Comparative Analysis: Global CINV Drugs Market Revenue, by Geography, 2013 & 2020 (Value %)
  • FIG. 4 Pathogenesis of CINV
  • FIG. 5 Unmet Needs in the CINV Market
  • FIG. 6 Comparative Analysis: Global CINV Drugs Market Revenue, by Major Drugs, 2013 & 2020 (Value %)
  • FIG. 7 Global Aloxi Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 8 Global Zofran Generic Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 9 Global Kytril Generic Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 10 Global Emend Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 11 Global Akynzeo Market Revenue, 2015 - 2020 (USD Million)
  • FIG. 12 Global SUSTOL Market Revenue, 2016 - 2020 (USD Million)
  • FIG. 13 Primary Efficacy Results: Complete Response with Patients Receiving MEC
  • FIG. 14 Primary Efficacy Results: Complete Response with Patients Receiving HEC
  • FIG. 15 Global Rolapitant Market Revenue, 2015 - 2020 (USD Million)
  • FIG. 16 North America CINV Drugs Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 17 Europe CINV Drugs Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 18 Asia-Pacific CINV Drugs Market Revenue, 2012 - 2020 (USD Million)
  • FIG. 19 RoW CINV Drugs Market Revenue, 2012 - 2020 (USD Million)

List of Tables

  • TABLE 1 List of Abbreviations
  • TABLE 2 Market Snapshot: Global CINV Existing and Pipeline Drugs Market (2013 & 2020)
  • TABLE 3 Chemotherapy Induced Nausea and Vomiting (CINV): Subtypes and Description
  • TABLE 4 Treatment Recommendations for CINV
  • TABLE 5 Event Impact Analysis: Global CINV Drugs Market
  • TABLE 6 Global CINV Drugs Market Revenue, by Major Drugs, 2012 - 2020 (USD Million)
  • TABLE 7 Global CINV Estimated Patient Pool, by Major Drugs, 2012 - 2020 (Thousands)
  • TABLE 8 SWOT Analysis for SUSTOL
  • TABLE 9 Efficacy of SUSTOL with Difficult Chemo Regimens
  • TABLE 10 SWOT Analysis for Rolapitant
  • TABLE 11 Overview of Rolapitant Efficacy Analysis
  • TABLE 12 Global CINV Drugs Market Revenue, by Geography, 2012 - 2020 (USD Million)
  • TABLE 13 Global CINV Estimated Patient Pool, by Geography, 2012 - 2020 (Thousands)
  • TABLE 14 North America CINV Pipeline Drugs Market Revenue, 2015 - 2020 (USD Million)
  • TABLE 15 North America CINV Estimated Patient Pool, by Pipeline Drug, 2015 - 2020 (Thousands)
  • TABLE 16 Europe CINV Pipeline Drugs Market Revenue, 2016 - 2020 (USD Million)
  • TABLE 17 Europe CINV Estimated Patient Pool, by Pipeline Drug, 2016 - 2020 (Thousands)
  • TABLE 18 GlaxoSmithKline plc: Expenses & Revenue, 2011 - 2013 (USD Million)
  • TABLE 19 Helsinn Holding S.A.: Pipeline Product Portfolio
  • TABLE 20 Heron Therapeutics, Inc.: Expenses & Revenue, 2011 - 2013 (USD Million)
  • TABLE 21 Heron Therapeutics, Inc.: Pipeline Product Portfolio
  • TABLE 22 Merck & Co., Inc.: Expenses & Revenue, 2011 - 2013 (USD Million)
  • TABLE 23 Tesaro, Inc.: Expenses & Revenue, 2011 - 2013 (USD Million)
  • TABLE 24 Tesaro, Inc.: Pipeline Product Portfolio
Back to Top